title: High-throughput screening for small-molecule modulators of inward rectifier potassium channels.
abstract: Specific members of the inward rectifier potassium (Kir) channel family are postulated drug targets for a variety of disorders, including hypertension, atrial fibrillation, and pain. For the most part, however, progress toward understanding their therapeutic potential or even basic physiological functions has been slowed by the lack of good pharmacological tools. Indeed, the molecular pharmacology of the inward rectifier family has lagged far behind that of the S4 superfamily of voltage-gated potassium (Kv) channels, for which a number of nanomolar-affinity and highly selective peptide toxin modulators have been discovered. The bee venom toxin tertiapin and its derivatives are potent inhibitors of Kir1.1 and Kir3 channels, but peptides are of limited use therapeutically as well as experimentally due to their antigenic properties and poor bioavailability, metabolic stability and tissue penetrance. The development of potent and selective small-molecule probes with improved pharmacological properties will be a key to fully understanding the physiology and therapeutic potential of Kir channels. The Molecular Libraries Probes Production Center Network (MLPCN) supported by the National Institutes of Health (NIH) Common Fund has created opportunities for academic scientists to initiate probe discovery campaigns for molecular targets and signaling pathways in need of better pharmacology. The MLPCN provides researchers access to industry-scale screening centers and medicinal chemistry and informatics support to develop small-molecule probes to elucidate the function of genes and gene networks. The critical step in gaining entry to the MLPCN is the development of a robust target- or pathway-specific assay that is amenable for high-throughput screening (HTS). Here, we describe how to develop a fluorescence-based thallium (Tl(+)) flux assay of Kir channel function for high-throughput compound screening. The assay is based on the permeability of the K(+) channel pore to the K(+) congener Tl(+). A commercially available fluorescent Tl(+) reporter dye is used to detect transmembrane flux of Tl(+) through the pore. There are at least three commercially available dyes that are suitable for Tl(+) flux assays: BTC, FluoZin-2, and FluxOR. This protocol describes assay development using FluoZin-2. Although originally developed and marketed as a zinc indicator, FluoZin-2 exhibits a robust and dose-dependent increase in fluorescence emission upon Tl(+) binding. We began working with FluoZin-2 before FluxOR was available and have continued to do so. However, the steps in assay development are essentially identical for all three dyes, and users should determine which dye is most appropriate for their specific needs. We also discuss the assay's performance benchmarks that must be reached to be considered for entry to the MLPCN. Since Tl(+) readily permeates most K(+) channels, the assay should be adaptable to most K(+) channel targets.
authors: Department of Pharmacology, Vanderbilt University School of Medicine, USA.
authors: Rene
authors: R
authors: Raphemot
authors: C David
authors: CD
authors: Weaver
authors: Jerod S
authors: JS
authors: Denton
mesh_terms: D005456:Fluorescent Dyes / Q000737:chemistry; D057809:HEK293 Cells; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D024661:Potassium Channels, Inwardly Rectifying / Q000737:chemistry* / Q000378:metabolism; D013793:Thallium / Q000737:chemistry / Q000378:metabolism
chemical_list: D005456:Fluorescent Dyes; D024661:Potassium Channels, Inwardly Rectifying; D013793:Thallium
references: Biochemistry. 1999 Oct 26;38(43):14286-93
references: 10572003
references: J Cardiovasc Pharmacol. 2008 Aug;52(2):129-35
references: 18670367
references: J Biomol Screen. 2004 Dec;9(8):671-7
references: 15634793
references: Curr Pharm Biotechnol. 2010 Nov;11(7):764-78
references: 20809896
references: Mol Pharmacol. 2009 Nov;76(5):1094-103
references: 19706730
references: Toxicon. 2007 Feb;49(2):213-30
references: 17097703
references: Mol Pharmacol. 2008 Apr;73(4):1213-24
references: 18171729
references: Mol Pharmacol. 2011 Jan;79(1):42-50
references: 20926757
references: Front Pharmacol. 2011 Nov 30;2:75
references: 22275899
references: Biochemistry. 1998 Sep 22;37(38):13291-9
references: 9748337
references: Future Med Chem. 2010 May;2(5):757-74
references: 20543968